These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 24909677)

  • 1. Lead identification of benzimidazolone and azabenzimidazolone arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists.
    Miah AH; Abas H; Begg M; Marsh BJ; O'Flynn DE; Ford AJ; Percy JM; Procopiou PA; Richards SA; Rumley SA
    Bioorg Med Chem; 2014 Aug; 22(15):4298-311. PubMed ID: 24909677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of pyrazolopyrimidine arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists.
    Miah AH; Champigny AC; Graves RH; Hodgson ST; Percy JM; Procopiou PA
    Bioorg Med Chem; 2017 Oct; 25(20):5327-5340. PubMed ID: 28801066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lead identification and structure-activity relationships of heteroarylpyrazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.
    Miah AH; Copley RC; O'Flynn D; Percy JM; Procopiou PA
    Org Biomol Chem; 2014 Mar; 12(11):1779-92. PubMed ID: 24515101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation.
    Procopiou PA; Ford AJ; Graves RH; Hall DA; Hodgson ST; Lacroix YM; Needham D; Slack RJ
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2730-3. PubMed ID: 22437117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.
    Procopiou PA; Barrett JW; Barton NP; Begg M; Clapham D; Copley RC; Ford AJ; Graves RH; Hall DA; Hancock AP; Hill AP; Hobbs H; Hodgson ST; Jumeaux C; Lacroix YM; Miah AH; Morriss KM; Needham D; Sheriff EB; Slack RJ; Smith CE; Sollis SL; Staton H
    J Med Chem; 2013 Mar; 56(5):1946-60. PubMed ID: 23409871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule antagonists of the CC chemokine receptor 4 (CCR4).
    Burdi DF; Chi S; Mattia K; Harrington C; Shi Z; Chen S; Jacutin-Porte S; Bennett R; Carson K; Yin W; Kansra V; Gonzalo JA; Coyle A; Jaffee B; Ocain T; Hodge M; LaRosa G; Harriman G
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3141-5. PubMed ID: 17395464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists capable of inducing receptor endocytosis.
    Shukla L; Ajram LA; Begg M; Evans B; Graves RH; Hodgson ST; Lynn SM; Miah AH; Percy JM; Procopiou PA; Richards SA; Slack RJ
    Eur J Med Chem; 2016 Jun; 115():14-25. PubMed ID: 26991939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5.
    Andrews G; Jones C; Wreggett KA
    Mol Pharmacol; 2008 Mar; 73(3):855-67. PubMed ID: 18042736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of thiourea derivatives and carbonyl-2-aminothiazole derivatives for potential CCR4 antagonists using capillary zone electrophoresis.
    Zhang S; Qi H; Yakufu P; Zhao F; Ling X; Xiao J; Wang Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jan; 879(1):75-82. PubMed ID: 21144808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists.
    Baker J; Bingham M; Blackburn-Munro R; Cai J; Craighead M; Gilfillan R; Goan K; Jaap D; Milne R; Morphy JR; Napier S; Presland J; Spinks G; Thomson F
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3603-7. PubMed ID: 21601454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel CC chemokine receptor 4 antagonist RS-1154 inhibits ovalbumin-induced ear swelling in mice.
    Nakagami Y; Kawashima K; Yonekubo K; Etori M; Jojima T; Miyazaki S; Sawamura R; Hirahara K; Nara F; Yamashita M
    Eur J Pharmacol; 2009 Dec; 624(1-3):38-44. PubMed ID: 19818758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives.
    Schaus JM; Thompson DC; Bloomquist WE; Susemichel AD; Calligaro DO; Cohen ML
    J Med Chem; 1998 May; 41(11):1943-55. PubMed ID: 9599243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines.
    Yokoyama K; Ishikawa N; Igarashi S; Kawano N; Masuda N; Hamaguchi W; Yamasaki S; Koganemaru Y; Hattori K; Miyazaki T; Ogino S; Matsumoto Y; Takeuchi M; Ohta M
    Bioorg Med Chem; 2009 Jan; 17(1):64-73. PubMed ID: 19081254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin.
    Raboisson P; Manthey CL; Chaikin M; Lattanze J; Crysler C; Leonard K; Pan W; Tomczuk BE; Marugán JJ
    Eur J Med Chem; 2006 Jul; 41(7):847-61. PubMed ID: 16697080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent CCR4 antagonists: Synthesis and structure-activity relationship study of 2,4-diaminoquinazolines.
    Yokoyama K; Ishikawa N; Igarashi S; Kawano N; Hattori K; Miyazaki T; Ogino S; Matsumoto Y; Takeuchi M; Ohta M
    Bioorg Med Chem; 2008 Jul; 16(14):7021-32. PubMed ID: 18539035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR2 receptor antagonists: optimization of biaryl sulfonamides to increase activity in whole blood.
    Wang GZ; Haile PA; Daniel T; Belot B; Viet AQ; Goodman KB; Sha D; Dowdell SE; Varga N; Hong X; Chakravorty S; Webb C; Cornejo C; Olzinski A; Bernard R; Evans C; Emmons A; Briand J; Chung CW; Quek R; Lee D; Gough PJ; Sehon CA
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7291-4. PubMed ID: 22047688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors.
    Davies MN; Bayry J; Tchilian EZ; Vani J; Shaila MS; Forbes EK; Draper SJ; Beverley PC; Tough DF; Flower DR
    PLoS One; 2009 Nov; 4(11):e8084. PubMed ID: 20011659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel azaindazole CCR1 antagonist clinical candidates.
    Harcken C; Kuzmich D; Cook B; Mao C; Disalvo D; Razavi H; Swinamer A; Liu P; Zhang Q; Kukulka A; Skow D; Patel M; Patel M; Fletcher K; Sherry T; Joseph D; Smith D; Canfield M; Souza D; Bogdanffy M; Berg K; Brown M
    Bioorg Med Chem Lett; 2019 Feb; 29(3):441-448. PubMed ID: 30595446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent CCR4 antagonists: synthesis, evaluation, and docking study of 2,4-diaminoquinazolines.
    Yokoyama K; Ishikawa N; Igarashi S; Kawano N; Masuda N; Hattori K; Miyazaki T; Ogino S; Orita M; Matsumoto Y; Takeuchi M; Ohta M
    Bioorg Med Chem; 2008 Sep; 16(17):7968-74. PubMed ID: 18694645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of chemokine receptor CCR4 antagonist.
    Purandare AV; Gao A; Wan H; Somerville J; Burke C; Seachord C; Vaccaro W; Wityak J; Poss MA
    Bioorg Med Chem Lett; 2005 May; 15(10):2669-72. PubMed ID: 15863339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.